U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07232732) titled 'A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity' on Nov. 14.
Brief Summary: The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
Study Start Date: Oct. 27
Study Type: INTERVENTIONAL
Condition:
Healthy
Obesity
Overweight
Intervention:
DRUG: LY3549492
Administered orally
Recruitment Status: RECRUITING
Sponsor: Eli Lilly and Company
Published by HT Digital Content Services with per...